APR-1051’s Emerging Best-in-Class WEE1 Profile Underpins Buy Rating on Aprea Therapeutics

Aprea Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $5.00 price target.

Jason McCarthy has given his Buy rating due to a combination of factors related to Aprea’s lead WEE1 inhibitor, APR-1051, and its emerging best‑in‑class profile. He notes that, in comparable endometrial and colorectal cancer cases, APR-1051 achieved similar or better tumor shrinkage than Zentalis’ azenosertib at substantially lower doses, while maintaining a notably cleaner safety and tolerability profile.

McCarthy also emphasizes that APR-1051 is still in dose escalation, showing dose‑responsive activity, early partial responses, and no meaningful toxicity issues through the 220 mg cohort, whereas azenosertib appears constrained by safety at higher, intermittently dosed levels. In his view, this dynamic increases the probability that APR-1051 will secure a superior therapeutic window within the WEE1 class, analogous to how the leading PARP inhibitor ultimately dominated its market, thereby supporting a favorable risk‑reward and a Buy recommendation on Aprea shares.

In another report released on January 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APRE in relation to earlier this year.